REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/BPC-157 Study Shows Promise in Accelerating Recovery from Hamstring Injuries
Back to Research Library

BPC-157 Study Shows Promise in Accelerating Recovery from Hamstring Injuries

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

BPC-157 Study Shows Promise in Accelerating Recovery from Hamstring Injuries

A new clinical trial investigating pentadecapeptide BPC 157 for treating acute hamstring muscle strains has begun recruiting participants. Sponsored by Hudson Biotech, this Phase 2 study aims to evaluate whether BPC-157 can expedite structural healing and improve functional recovery compared to a placebo.

Background

Hamstring muscle injuries are common among athletes and individuals engaged in high-intensity physical activities. These injuries can cause significant downtime and disrupt training schedules. Currently, rehabilitation programs focus on gradual reconditioning of the injured muscles, but there is increasing interest in exploring peptide therapy as an adjunctive treatment to accelerate recovery.

BPC-157 is a synthetic pentadecapeptide that has shown promise in various preclinical studies for its anti-inflammatory and tissue-healing properties. Its potential benefits include reducing muscle inflammation and promoting faster regeneration of damaged tissues, which could be particularly useful in sports medicine where quick return-to-play timelines are crucial.

Key Details

The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study involving participants with acute grade II hamstring muscle strains. The primary objective is to assess whether BPC-157 can reduce the time required for full recovery and enhance structural healing as measured by MRI scans at Day 14 post-injury.

Participants will receive either BPC-157 or a placebo in addition to following a standardized rehabilitation program that includes physical therapy sessions. The study period is relatively short, lasting only two weeks, but this timeframe allows researchers to capture early recovery markers and changes in injury volume.

The primary endpoints of the trial are the time needed for athletes to return to unrestricted sports activities and the reduction in MRI-assessed injury volume at Day 14 compared to baseline measurements. Secondary outcomes will include pain levels, muscle strength assessments, and patient-reported functional status during follow-up visits.

Key Takeaways

  • Accelerated Recovery: The study aims to determine if BPC-157 can help athletes recover faster from hamstring injuries.
  • Structural Healing: Researchers will measure the effectiveness of BPC-157 in reducing injury volume using MRI scans.
  • Double-blind, Placebo-Controlled Design: This rigorous trial design helps ensure unbiased results and adds credibility to the findings.
  • Standardized Rehabilitation Program: Participants receive consistent care alongside peptide therapy, allowing for fair comparison with placebo.

What This Means

This clinical trial represents a significant step forward in exploring BPC-157’s potential as an effective treatment option for hamstring muscle injuries. If successful, it could provide athletes and clinicians with a new tool to speed up recovery times and minimize downtime associated with these common sports-related injuries.

The results of this study will be closely watched by the peptide research community, as positive outcomes could pave the way for further investigations into BPC-157’s therapeutic applications. Additionally, understanding its mechanisms may lead to broader implications in regenerative medicine and tissue repair beyond sports injuries.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07437547) — Published 2026-02-27

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.